One Stop Solution For In-Depth Market Research Reports

詳細な市場調査レポートのワンストップソリューション

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Artemisinin Combination Therapy Market

[ 英語タイトル ] Artemisinin Combination Therapy Market - Growth, Trends, and Forecast (2020 - 2025)


Product Code : MDHC0089101
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 111
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Cipla Ltd.
- Desano Inc.
- Hovid Berhad
- KPC Pharmaceuticals
- Guilin Pharmaceutical(Fosun Pharmaceutical )
- Novartis AG
- Sanofi S.A.

[Report Description]

Artemisinin combination therapy (ACT) is used for the treatment of Plasmodium falciparum malaria. This market has been growing in recent years due to the high prevalence of malaria, especially in developing and under-developing countries.

According to the “World Malaria Report 2018” by World Health Organization (WHO), there were an estimated 219 million cases and nearly 435,000 related deaths in 2017 and most of the malaria cases were attributed to Plasmodium falciparum. Hence the high prevalence of malaria is driving the growth of this market. Other factors like an increase in awareness initiatives by governments and research for new anti-malarial drugs and therapies are also helping this market grow. However, side-effects of anti-malarial drugs and the presence of counterfeit and substandard drugs are restraining the growth of this market.

Key Market Trends

Artemether-Lumefantrine Segment is Expected to Dominate the Market During the Forecast Period

Artemether-Lumefantrine is a combination of the two medications artemether and lumefantrine. It is used to treat malaria caused by Plasmodium falciparum that is not treatable with chloroquine. They were both developed in China. It is one of the drugs on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.

The World Health Organization recommends that uncomplicated Plasmodium falciparum malaria should be treated with an artemisinin- lumefantrine combination therapy. Artemether-lumefantrine is the most widely used Artemisinin Combination Therapy (ACT), accounting for 73% of global ACT procurement according to an article by Frank Kloprogge et al published in PLoS Medicine Journal 2018, which makes it one of the most widely used anti-infective agents in the world today. As this combination is used as the first-line drug for malaria in most countries, it is expected to cover a large share in the global artemisinin combination therapy market.

Middle East and Africa is Expected to Show a High Growth During the Forecast Period

The Middle East and Africa held the largest share in the artemisinin combination therapy market due to the presence of a large production base of artemisinin herbs and rising demand in malaria-endemic countries that are contributing to the growth of the market.

According to the World Health Organization (WHO), there were an estimated 219 million cases of malaria worldwide in 2017, out of which WHO African Region carried a disproportionately high share of the global malaria burden. In 2017, the region contributed 92% of malaria cases and 93% of malaria deaths. The WHO Eastern Mediterranean Region was home for nearly 2% of the global malaria cases. Owing to these factors, the Middle East and Africa region is expected to have one of the largest shares in the artemisinin combination therapy market.

Competitive Landscape

Majority of the Artemisinin Combination Therapy drugs are being manufactured by the global key players. Market leaders with more funds for research and better distribution system have established their position in the market. These global players are mostly based in developed countries like United States, United Kingdom, France, Germany and Japan.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Prevalence of Malaria in Developing and Under Developed Countries
4.2.2 Awareness Initiatives Undertaken by the Governments
4.2.3 Increasing Research for New Drugs and New Combinations Therapies
4.3 Market Restraints
4.3.1 Side Effects of Anti-malaria Drugs
4.3.2 Presence of Counterfeit and Substandard Antimalarial Drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Combination Therapy Type
5.1.1 Artemether-Lumefantrine
5.1.2 Artesunate-Amodiaquine
5.1.3 Artesunate-Pyronaridine
5.1.4 Artesunate-Sulfadoxine-Pyrimethamine
5.1.5 Others
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Cipla Ltd.
6.1.2 Desano Inc.
6.1.3 Hovid Berhad
6.1.4 KPC Pharmaceuticals
6.1.5 Guilin Pharmaceutical(Fosun Pharmaceutical )
6.1.6 Novartis AG
6.1.7 Sanofi S.A.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

渋谷データカウント

渋谷データカウントは、最も信頼性が高く最新の調査分析レポートを確実に提供する経験豊富な調査専門家のグローバルチームが提供する、さまざまな業界のさまざまな市場調査レポートを提供する再販代理店です。

Recommended reports

+